Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 401–500 of 1,000
Han, J., Cheng, F., Yang, Z., & Dryhurst, G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.731683.x · Cited by 74
Wang, T., Liu, Y., Wang, X., Yang, N., Zhu, H., & Zuo, P. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.69 · Cited by 84
Emerging Roles of Complement Protein C1q in Neurodegeneration
Cho, K. (2019) · Aging and disease · doi:10.14336/ad.2019.0118 · Cited by 72
“The major feature of PD is a progressive demise of dopaminergic neurons in the substantia nigra pars compacta (SNc) [86].”
BackgroundInduction and specification of midbrain dopaminergic cells: focus on SHH, FGF8, and TGF-?
Roussa, E., & KRIEGLSTEIN, K. G. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0916-4 · Cited by 85
Superoxide dismutase and Parkinson's disease
Ceballos-Picot, I., Lafon, M., Javoy-Agid, F., Hirsch, É. C., Nicole, A., Sinet, P., & Agid, Y. (1990) · The Lancet · doi:10.1016/0140-6736(90)91099-v · Cited by 73
Self-citationThe role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases
Possemato, E., Barbera, L. L., Nobili, A., Krashia, P., & D’Amelio, M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101907 · Cited by 78
Burtscher, J., Zangrandi, L., Schwarzer, C., & Gnaiger, E. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.10.007 · Cited by 72
Lee, Y., Park, H. R., Chun, H. J., & Lee, J. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23544 · Cited by 72
“, 1999), and in particular with selective loss of dopaminergic neurons in the nigrostriatal pathway (Hirsch et al., 1988).”
BackgroundPlotegher, N., Kumar, D., Tessari, I., Brucale, M., Munari, F., Tosatto, L., Belluzzi, E., Greggio, E., Bisaglia, M., Capaldi, S., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu275 · Cited by 69
Spared error-related potentials in mild to moderate Parkinson’s disease
Holroyd, C. B., Praamstra, P., Plat, E., & COLES, M. G. H. (2002) · Neuropsychologia · doi:10.1016/s0028-3932(02)00052-0 · Cited by 84
“Although degeneration of the midbrain dopamine nuclei is the hallmark neuropathological feature of Parkinson’s disease, this deterioration is not spatially uniform across the midbrain dopamine nuclei [23].”
BackgroundRegional brain susceptibility to neurodegeneration: what is the role of glial cells?
Cirillo, G., Cragnolini, A. B., Lampitella, G., Virtuoso, A., Viscovo, I., Panetsos, F., & Papa, M. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.268897 · Cited by 81
“Neurons in the ventral and lateral SNpc, for example, are much more susceptible than dopaminergic neurons in the ventral tegmental area (VTA) or in the hypothalamus (Hirsch et al., 1988).”
BackgroundMichel, P. P., Toulorge, D., Guerreiro, S., & Hirsch, É. C. (2013) · The FASEB Journal · doi:10.1096/fj.12-220418 · Cited by 70
“This is of interest since, as already mentioned TH disappears from a population of vulnerable but still viable SN DA neurons in PD (38).”
BackgroundKrashia, P., Nobili, A., & D'Amelio, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00123 · Cited by 71
Afonso-Oramas, D., Cruz-Muros, I., de la Rosa, D. Á., Abreu, P., Giráldez, T., Castro-Hernández, J., Salas-Hernández, J., Lanciego, J. L., Rodríguez, M., & González-Hernández, T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.002 · Cited by 70
“…of mesostriatal projections (Fallon and Loughlin, 1982; Joel and Weiner, 2000) and their degeneration pattern in PD (Bernheimer et al., 1973; Hirsch et al., 1988; Damier et al., 1999b) and in monkey (Burns et al., 1983; German et al., 1992) and rodent (Hung and Lee, 1996; Rodriguez et al.,…”
Qu, D., Hage, A., Don-Carolis, K., Huang, E., Joselin, A. P., Safarpour, F., Marcogliese, P. C., Rousseaux, M. W. C., Hewitt, S. J., Huang, T., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677815 · Cited by 74
“Parkinson disease (PD)(2) is the second most common neurodegenerative disorder, characterized by selective loss of the pigmented dopaminergic neurons of the substantia nigra pars compacta (1).”
BackgroundMackie, P. M., Lebowitz, J., Saadatpour, L., Nickoloff, E., Gaskill, P. J., & Khoshbouei, H. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.020 · Cited by 77
Is There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease?
Barzilai, A., Melamed, E., & Shirvan, A. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1010991020245 · Cited by 76
“While little is known about the structure and possible physiological function of NM, interest in the substance was fuelled by a report that NM-containing neurons are preferentially lost in PD (Hirsch et al., 1988).”
BackgroundVolpe, B. T., Wildmann, J., & Altar, C. A. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00424-7 · Cited by 70
Lorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
“regions has also been reported [28–30], preferentially occurring within neurons that contain the dark-brown cytoplasmic pigment neuromelanin (NM) [29,31].”
BackgroundIron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
Riederer, P. F., Monoranu, C., Strobel, S., Iordache, T., & Sian‐Hülsmann, J. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02414-z · Cited by 72
McCormack, A. L., Atienza, J. G., Langston, J. W., & Monte, D. A. D. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.03.069 · Cited by 69
Marchionini, D. M., Lehrmann, E., Chu, Y., He, B., Sortwell, C. E., Becker, K. G., Freed, W. J., Kordower, J. H., & Collier, T. J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.028 · Cited by 69
Melanin and neuromelanin binding of drugs and chemicals: toxicological implications
Karlsson, O., & Lindquist, N. G. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1757-0 · Cited by 81
Wang, S., Zou, C., Fu, L., Wang, B., An, J., Song, G., Wu, J., Tang, X., Li, M., Zhang, J., et al. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.12 · Cited by 69
Wang, J., Bankiewicz, K. S., Plunkett, R. J., & Oldfield, E. H. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.80.3.0484 · Cited by 69
Riederer, P. F., Nagatsu, T., Youdim, M. B. H., Wulf, M., Dijkstra, J. M., & Sian‐Hülsmann, J. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02630-9 · Cited by 74
“A loss of 60% or more of the NMcontaining dopaminergic neurons is warranted for the manifestation of the motor dysfunction characteristic of the disease (Bernheimer et al. 1973; Hirsch et al. 1988).”
BackgroundZesiewicz, T., Sullivan, K. L., Maldonado, J. L., Tatum, W. O., & Hauser, R. A. (2005) · Movement Disorders · doi:10.1002/mds.20563 · Cited by 70
Neural degeneration and the transport of neurotransmitters
Edwards, R. H. (1993) · Annals of Neurology · doi:10.1002/ana.410340504 · Cited by 76
Zhang, Y., He, X., Wu, X., Lei, M., Wei, Z., Zhang, X., Wen, L., Xu, P., Li, S., & Qu, S. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.491 · Cited by 66
Paillé, V., Henry, V., Lescaudron, L., Brachet, P., & Damier, P. (2007) · Movement Disorders · doi:10.1002/mds.21308 · Cited by 77
“This rat model of PD shares most of the clinical and pathological characteristics of the human disease: bilateral lesions of DA-containing neurons in the posterolateral part of the SNpc with a relative preservation of the VTA, motor abnormalities greatly improved under Ldopa treatment and, in animals with the most sev…”
BackgroundInfluentialShamoto‐Nagai, M., Maruyama, W., Yi, H. L., Akao, Y., Tribl, F., Gerlach, M., Osawa, T., Riederer, P. F., & Naoi, M. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0410-5 · Cited by 71
The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration
Fu, Y., Paxinos, G., WATSON, C. R. R., & Halliday, G. M. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.02.001 · Cited by 74
“…shows that there are about 200,000– 420,000 TH-specific neurons bilaterally in the adult human SNC and about 60,000–65,000 TH-positive neurons in the adult human VTA (Halliday and Tork, 1986; Hirsch et al., 1988; Chu et al., 2002; Hardman et al., 2002; Marchitti et al., 2007).”
Kish, S. J., Boileau, I., Callaghan, R. C., & Tong, J. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13363 · Cited by 69
“…by loss of nigral cell bodies that contain dopamine markers (the pigment neuromelanin formed as part of dopamine metabolism; the biosynthetic enzyme tyrosine hydroxylase) (Bernheimer et al., 1973; Hirsch et al., 1988; Fearnley & Lees, 1991; Pakkenberg et al., 1991; Rudow et al., 2008).”
BackgroundTimmer, M., Müller-Ostermeyer, F., Kloth, V., Winkler, C., Grothe, C., & Nikkhah, G. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.013 · Cited by 76
Evidence of Functional Zinc Deficiency in Parkinson's Disease
Forsleff, L., Schauss, A. G., Bier, I. D., & Stuart, S. (1999) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.1999.5.57 · Cited by 66
“…cells in the melanized neurons of the substan-nigra, with more moderate losses of dopamine tia nigra, resulting hi severe reduction of foimd ui the amygdaloid nucleus, lateral hy-dopamine in all components of the basal gan-pothalamus, and medial olfactory region glia (Hirsch et al., 1988).”
Pardo, B., Mena, M. A., Fahn, S., & de Yébenes, J. G. (1993) · Movement Disorders · doi:10.1002/mds.870080305 · Cited by 65
Blunt, S. B., Jenner, P. G., & MARSDEN, C. D. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90420-s · Cited by 66
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Greene, J. G. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5859 · Cited by 65
“…neurons in the pontine locus ceruleus, cholinergic and noradrenergic neurons in sympathetic centers in the spinal cord and periphery, and cholinergic neurons in the dorsal motor nucleus of the vagus nerve (DMV) in the medulla, among other areas (19, 86, 95, 96, 103, 104, 119, 131, 209).”
EPR investigations of the iron domain in neuromelanin
Aime, S., Bergamasco, B., Biglino, D., Digilio, G., Fasano, M., Giamello, E., & Lopiano, L. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00014-8 · Cited by 72
Aoki, E., Yano, R., Yokoyama, H., Kato, H., & Araki, T. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.10.004 · Cited by 71
Chocyk, A., Dudys, D., Przyborowska, A., Majcher‐Maślanka, I., Maćkowiak, M., & Wędzony, K. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.11.037 · Cited by 73
TGF-β promotes survival on mesencephalic dopaminergic neurons in cooperation with Shh and FGF-8
Roussa, E., Farkas, L. M., & KRIEGLSTEIN, K. G. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.03.006 · Cited by 75
Takahashi, H., Watanabe, Y., Tanaka, H., Mihara, M., Mochizuki, H., Liu, T., Wang, Y., & Tomiyama, N. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180037 · Cited by 71
Kästner, A., Hirsch, É. C., Herrero, M. T., Javoy-Agid, F., & Agid, Y. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03616.x · Cited by 73
Self-citationSalmon, E., Brooks, D. J., Leenders, K. L., Turton, D. R., Hume, S. P., Cremer, J. E., Jones, T., & Frackowiak, R. S. J. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.59 · Cited by 65
Kostuk, E. W., Cai, J., & Iacovitti, L. (2019) · Glia · doi:10.1002/glia.23627 · Cited by 64
Neuroprotective effects of hydrogen sulfide and the underlying signaling pathways
Chen, W., Niu, Y., Jiang, W.-Z., Tang, H.-L., Zhang, C., Xia, Q.-M., & Tang, X. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0051 · Cited by 67
“PD is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra (SN) (Hirsch et al., 1988).”
BackgroundChen, D., Zhang, X.-Y., Sun, J., Cong, Q.-J., Chen, W.-X., Ahsan, H. M., Gao, J., & Qian, J.-J. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.188 · Cited by 64
“The death of DA neurons in the substantia nigra is central to the pathology of PD, but the neurodegenerative mechanisms have not been fully elucidated (Hirsch et al., 1988).”
BackgroundDolichol is the major lipid component of human substantia nigra neuromelanin
Fedorow, H., Pickford, R., Hook, J. M., Double, K. L., Halliday, G. M., Gerlach, M., Riederer, P., & Garner, B. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02975.x · Cited by 64
“A complete understanding of neuromelanin biochemistry is crucial as it is the pigmented dopaminergic neurones of the SN that preferentially degenerate in idiopathic Parkinson’s disease (PD) (Hirsch et al. 1988).”
BackgroundInfluentialHsu, C.-Y., Hung, C.-S., Chang, H.-M., Liao, W.-C., Ho, S.-C., & Ho, Y.-J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.023 · Cited by 63
Butkovich, L. M., Houser, M. C., Chalermpalanupap, T., Porter‐Stransky, K. A., Iannitelli, A. F., Boles, J. S., Lloyd, G. M., Coomes, A. S., Eidson, L. N., Rodrigues, M. E. D. S., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1468-19.2020 · Cited by 69
Astaxanthin is neuroprotective in an aged mouse model of Parkinson’s disease
Grimmig, B. A., Daly, L., Subbarayan, M. S., Hudson, C., Williamson, R., Nash, K. R., & Bickford, P. C. (2017) · Oncotarget · doi:10.18632/oncotarget.23737 · Cited by 63
“None of these patients were diagnosed with PD, but together these observations suggest that normal aging creates a susceptibility and similarity to PD pathology [6, 7] Interestingly, the substantia nigra has unique physiological characteristics that distinguish this region from similar dopaminergic centers and render…”
BackgroundPasinetti, G. M., Osterburg, H. H., Kelly, A. B., Kohama, S., Morgan, D., Reinhard, J. F., Stellwagen, R. H., & Finch, C. E. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90045-d · Cited by 71
Masini, D., Plewnia, C., Bertho, M., Scalbert, N., Caggiano, V., & Fisone, G. (2021) · Biomedicines · doi:10.3390/biomedicines9060598 · Cited by 75
“The impairment of the nigrostriatal system produced by striatal injection of 6-OHDA is accompanied by a more limited damage in the VTA and nucleus accumbens, which is in line with the relative sparing of these structures observed in PD patients [81,82].”
BackgroundRolland, A., Tandé, D., Herrero, M., Luquin, M., Vazquez‐Claverie, M., Karachi, C., Hirsch, E. C., & François, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06220.x · Cited by 62
“Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta and adjacent dopaminergic areas (Hirsch et al. 1988), leading to dysfunction of the basal ganglia system and motor symptoms.”
Backgroundde Castro, A. A., Wiemes, B. P., MATHEUS, F. C., Lapa, F. D. R., Viola, G. G., Santos, A. R. S., Tasca, C. I., & Prediger, R. D. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.029 · Cited by 67
Nigral degeneration in parkinson's disease
Rinne, J. O. (1993) · Movement Disorders · doi:10.1002/mds.870080507 · Cited by 64
Distribution of manganese-dependent superoxide dismutase in the human brain
Zhang, P., Anglade, P., Hirsch, É. C., Javoy-Agid, F., & Agid, Y. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90234-8 · Cited by 60
Self-citationIron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis?
Lee, D. W., & Andersen, J. K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06470.x · Cited by 61
“Neuromelanin Seminal studies demonstrating the preferential loss of melanized dopaminergic neurons in the PD SN (Hirsch et al. 1988) led to a flurry of experiments to determine the cause of vulnerability of these neurons to neurodegeneration.”
BackgroundGrison, A., Zucchelli, S., Urzì, A., Zamparo, I., Lazarević, D., Pascarella, G., Roncaglia, P., Giorgetti, A., Garcia‐Esparcia, P., Vlachouli, C., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-729 · Cited by 63
Cholesterol – A putative endogenous contributor towards Parkinson's disease
Paul, R. K., Choudhury, A., & Borah, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.025 · Cited by 65
Neuronal distribution of intranuclear inclusions in Huntingtonʼs disease with adult onset
Gourfinkel‐An, I., Cancel‐Tassin, G., Duyckaerts, C. J., Faucheux, B. A., Hauw, J., Trottier, Y., Brice, A., Agid, Y., & Hirsch, É. C. (1998) · Neuroreport · doi:10.1097/00001756-199806010-00028 · Cited by 61
Self-citationHo, A., & Blum, M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6659 · Cited by 60
“Parkinson’s disease (PD) is a neurodegenerative disorder in which nigral dopamine (DA) neurons in the mesencephalon selectively degenerate, thus leading to a loss of DAergic innervation to the dorsal striatum (1, 9, 43).”
BackgroundRoussa, E., & KRIEGLSTEIN, K. G. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.106 · Cited by 60
Neuronal cell replacement in Parkinson’s disease
Hedlund, E., & Perlmann, T. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02155.x · Cited by 65
Atasoy, H. T., Nuyan, O., Tunç, T., et al. (2004) · PubMed · Cited by 60
FADD: A link between TNF family receptors and caspases in Parkinson’s disease
Hartmann, A., Prigent, A., Faucheux, B. A., Agid, Y., & Hirsch, É. C. (2002) · Neurology · doi:10.1212/wnl.58.2.308 · Cited by 60
Self-citationPathology of Parkinson’s Syndrome
Jellinger, K. A. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-73899-9_2 · Cited by 74
Choi, D., An, J., Jou, I., Park, S. M., & Joe, E.-H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.003 · Cited by 65
The pathobiological basis of depression in Parkinson disease: challenges and outlooks
Jellinger, K. A. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02559-5 · Cited by 84
“However, the majority of LC neurons can survive the pathological process for many years, in contrast to the abundant early neuronal loss in the SNc (Beach et al.”
BackgroundInfluentialBranchi, I., D’Andrea, I., Armida, M., Carnevale, D., Ajmone‐Cat, M. A., Pèzzola, A., Potenza, R. L., Morgese, M. G., Cassano, T., Minghetti, L., et al. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.020 · Cited by 61
Enochs, W. S., Nilges, M. J., & Swartz, H. M. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03538.x · Cited by 59
Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats
Braga, R., Kouzmine, I., Canteras, N. S., & Cunha, C. D. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.006 · Cited by 57
Figueiredo, C. P., Pamplona, F. A., Mazzuco, T. L., Aguiar, A. S., Walz, R., & Prediger, R. D. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833c8544 · Cited by 62
“intracytoplasmic, proteinaceous inclusions, termed Lewy bodies and dystrophic Lewy neuritis, in surviving neurons (Hirsch et al., 1988).”
BackgroundMachado, V., Haas, S. J.-P., Halbach, O. V. B. U., Wree, A., KRIEGLSTEIN, K. G., Unsicker, K., & Spittau, B. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.016 · Cited by 59
Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system
Kästner, A., Anglade, P., Bounaix, C., Damier, P., Javoy-Agid, F., Bromet, N., Agid, Y., & Hirsch, É. C. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90379-4 · Cited by 57
Self-citationMicroglia as therapeutic target in central nervous system disorders
Fatoba, O., Itokazu, T., & Yamashita, T. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.004 · Cited by 61
Mechanisms Underlying Brain Aging Under Normal and Pathological Conditions
Jin, M., & Cai, S. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00969-9 · Cited by 71
“When it comes to the relationship between mitochondria and pathological brain aging, PD should not be ignored [32, 33].”
BackgroundNagatsu, T., Nakashima, A., Watanabe, H., Ito, S., Wakamatsu, K., Zucca, F. A., Zecca, L., Youdim, M. B. H., Wulf, M., Riederer, P. F., et al. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02617-6 · Cited by 64
Selective and efficient electrochemical biosensing of ultrathin molybdenum disulfide sheets
Narayanan, T. N., Vusa, C. S. R., & Alwarappan, S. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/33/335702 · Cited by 56
Stuckenholz, V., Bacher, M., Balzer‐Geldsetzer, M., Alvarez‐Fischer, D., Oertel, W. H., Dodel, R. C., & Noelker, C. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120157 · Cited by 64
Ricke, K. M., Paß, T., Kimoloi, S., Fährmann, K., Jüngst, C., Schauss, A. C., Baris, O. R., Croon, M., Trifunović, A., Faelker, T. M. E., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1345-19.2019 · Cited by 60
“This specific decline can be further observed in PD patients (Hirsch et al., 1988; Damier et al., 1999), as well as in rodents, where the same specific neuron loss is induced by mitochondrial toxins like MPTP (German et al., 1992) or rotenone (Betarbet et al., 2000).”
BackgroundResultRole of activity‐dependent mechanisms in the control of dopaminergic neuron survival
Michel, P. P., Alvarez‐Fischer, D., Guerreiro, S., Hild, A., Hartmann, A., & Hirsch, É. C. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04424.x · Cited by 60
“…in the synthesis of dopamine which is induced by electrical activity (Nagamoto-Combs et al. 1997; Brosenitsch and Katz 2001) is almost undetectable in a population of morphologically intact DA neurons that are prone to degenerate in the brain of PD patients (Hirsch et al. 1988; Michel et al. 2002).”
BackgroundResultInfluentialα-Synuclein overexpression increases dopamine toxicity in BE(2)-M17 cells
Bisaglia, M., Greggio, E., Maric, D., Miller, D. W., Cookson, M., & Bubacco, L. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-41 · Cited by 59
“PD is a chronic and progressive disease caused by degeneration of several neuronal populations in the brain, most notably the dopaminergic neuromelanin-containing neurons of the substantia nigra (SN) pars compacta [ 1 ].”
BackgroundProtection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors
Weingarten, P., & Zhou, Q. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00263.x · Cited by 55
“In this regard, the increased susceptibility of highly melanized DA neurons to degeneration in PD (Hirsch et al. 1988) may be due to toxic levels of cytoplasmic DA consequent to a dysregulation of DA disposition, such as inadequate vesicular storage.”
BackgroundBean, A. J., Dagerlind, Å., Hökfelt, T. G. M., & Dobner, P. R. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90421-w · Cited by 61
Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
Ebanks, B., & Chakrabarti, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.854321 · Cited by 60
“Characterised by classical motor symptoms of resting tremor and bradykinesia, much of this is due to the degeneration of the dopaminergic neurons of the substantia nigra (Hirsch et al., 1988).”
BackgroundPerfusion Magnetic Resonance Imaging in Psychiatry
Théberge, J. (2008) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0b013e3181808140 · Cited by 56
“Regardless of the cause, the disease seems to involve a central mechanism, that is, the destruction or damage of dopaminergic neurons within the substantia nigra pars compacta.(92) These neurons are an essential component of the nigrostriatal dopamine pathway thought to control movement.”
BackgroundGene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease
Greene, J. G. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.112599 · Cited by 58
“Parkinson’s disease (PD), a common extrapyramidal movement disorder, is associated with selective neurodegeneration of substantia nigra (SN) dopamine neurons (Hirsch et al. 1988).”
BackgroundIron, melanin and dopamine interaction: relevance to parkinson's disease
Ben‐Shachar, D., & Youdim, M. B. H. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90038-t · Cited by 57
Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans
McRitchie, D. A., & Halliday, G. M. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00483-l · Cited by 54
Differential distribution of the normal and mutated forms of huntingtin in the human brain
Gourfinkel‐An, I., Cancel, G., Trottier, Y., Devys, D., Tora, L., Lutz, Y., Imbert, G., Saudou, F., Stevanin, G., Agid, Y., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420507 · Cited by 54
Self-citationParaquat induced activation of transcription factor AP-1 and apoptosis in PC12 cells
Li, X., & Sun, A. Y. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050137 · Cited by 55
“…al., 1991; Sofic et al., 1991) which may result in the production of deleterious free radicals (Cheng et al., 1994, 1996); 2) increased levels of malondialdehyde (Dexter et al., 1989) and lipid hydroperoxides (Dexter et al., 1994) and 3) loss of neuromelanin-containing cells (Hirsch et al., 1988).”
Faucheux, B. A., Hirsch, E. C., Villares, J., Selimi, F., Mouatt‐Prigent, A., Javoy‐Agid, F., Hauw, J. J., & Agid, Y. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03527.x · Cited by 54
Self-citationLoss of dopamine phenotype among midbrain neurons in L esch– N yhan disease
Göttle, M., Prudente, C. N., Fu, R., Sutcliffe, D. J., Pang, H., Cooper, D., Veledar, E., Glass, J. D., Gearing, M., Visser, J. E., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24191 · Cited by 60
“melanin-positive but TH-negative substantia nigra neurons in Parkinson disease and related Parkinsonian syndromes.(45) Such neurons were found with a frequency of 17% in Parkinson diseases and an even higher frequency of 64% in progressive supranuclear palsy.”
BackgroundThe lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed
Alavian, K. N., Jeddi, S., Naghipour, S. I., Nabili, P., Licznerski, P., & Tierney, T. S. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-27 · Cited by 60
Identification of L-ferritin in Neuromelanin Granules of the Human Substantia Nigra
Tribl, F., Asan, E., Arzberger, T., Tatschner, T., Langenfeld, E., Meyer, H. E., Bringmann, G., Riederer, P. F., Gerlach, M., & Marcus, K. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900006-mcp200 · Cited by 63
“Interest in this pigment has seen a resurgence in recent years because of a hypothesized link between NM and the especial vulnerability of NM-containing neurons of the substantia nigra pars compacta (SN) for cell death in Parkinson disease (PD) (2, 3).”
BackgroundIncubator embedded cell culture imaging system (EmSight) based on Fourier ptychographic microscopy
Kim, J., Henley, B. M., Kim, C. H., Lester, H. A., & Yang, C. (2016) · Biomedical Optics Express · doi:10.1364/boe.7.003097 · Cited by 53
A new brain dopamine‐deficient Drosophila and its pharmacological and genetic rescue
Cichewicz, K., Garren, E. J., Adiele, C., Aso, Y., Wang, Z., Wu, M., Birman, S., Rubin, G. M., & Hirsh, J. (2017) · Genes, Brain and Behavior · doi:10.1111/gbb.12353 · Cited by 53
“It has been known for decades that up to 80% of substantia nigra DA neurons degenerate in a human brain prior to expression of the locomotor symptoms of PD (Hirsch et al. 1988; Hornykiewicz 1966), although more recent studies suggest that only ∼30% of substantia nigra DA neurons and around 50–60% of their axon termina…”
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.